Close Menu

NEW YORK (GenomeWeb) – NeoGenomics today reported a 17 percent year-over-year rise in its Q3 revenues, beating the consensus Wall Street analyst estimate.

The cancer genetic testing company reported revenues of $69.1 million for the three months ended Sept. 30, up from restated revenues of $59.1 million in the year-ago period. The consensus Wall Street estimate was $66.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.